Overtreatment Common for Older Men With Prostate Cancer
By Dennis Thompson HealthDay Reporter
WEDNESDAY, Nov. 12, 2024 -- Overtreatment of prostate cancer is increasing in the United States among men with limited life expectancy, a new study reports.
Procedures like radiation therapy and prostate surgery are being employed more often in these men, causing side effects like incontinence and impotence without adding any more years to their lives, researchers found.
Two-thirds of men with intermediate-risk prostate cancer and nearly half of men with high-risk cancer are receiving treatment that frequently proves harmful and useless, they added.
“We found this pattern surprising,” said lead researcher Dr. Timothy Daskivich, director of urologic oncology research for Cedars-Sinai Medical Center in Los Angeles.
“Prostate cancer patients with life expectancies of less than five or 10 years were being subjected to treatments that can take up to a decade to significantly improve their chances of surviving cancer, despite guidelines recommending against treatment,” Daskivich added in a Cedars-Sinai news release.
This trend runs counter to efforts promoting “active surveillance” of prostate cancers in men where treatment would needlessly harm their quality of life.
This “watch-and-wait” approach is recommended for all prostate cancer patients who will likely die of some other cause, whether it’s men with low-risk, slow-growing cancer or those with more advanced cancer but only a few years of life left, researchers said.
“Use of active surveillance has increased over the last 15 years for men with low-risk prostate cancer, and it is now the most common treatment for these men,” Daskivich said. “This approach allows these patients to avoid the risks of urinary incontinence, erectile dysfunction and other potential side effects of surgery and radiation therapy.”
For this study, researchers analyzed medical data on nearly 244,000 men diagnosed in VA hospitals with prostate cancer between 2000 and 2019.
Results show that radiation therapy or surgery for men with low-risk prostate cancers decreased from 37% to 15% during that period, as recommended.
However, treatment for intermediate-risk prostate cancer increased from 38% to 60%, researchers found.
And in men with average life expectancies of less than five years, treatment for high-risk prostate cancer increased from 17% to 47%.
Radiation therapy is most often used in unnecessary prostate cancer treatment, employed 80% of the time, researchers found.
The use of radiation therapy increased from 16% to 39% among men with a life expectancy of less than five years, the study showed.
The new study was published Nov. 11 in the journal JAMA Internal Medicine.
To prevent overtreatment, Daskivich and his team have proposed a “trifecta” method for discussing a prostate cancer prognosis with patients.
In this method, the doctor would discuss the likelihood of dying from the cancer with treatment versus without treatment, given the patient’s individual life expectancy.
“Our goal is to encourage clinicians to make longevity part of the discussion about the best treatment options so that prostate cancer patients with limited life expectancies can make educated choices,” Daskivich said.
“A patient may be given this data and choose to pursue surgery or radiation treatments regardless of a limited probability of benefit. Another patient may take a different course,” Daskivich added.
“Every individual is different, and statistical averages for lifespan, treatment effectiveness and cancer risk cannot predict outcomes with certainty,” Daskivich concluded. “But patients should be given the opportunity to make informed decisions with the best possible information.”
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-11-14 00:00
Read more
- First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
- Nursing-Sensitive Quality Indicators Negatively Impacted by Pandemic
- Weight-Loss Surgeries Decline 25% as More Americans Turn to GLP-1 Meds
- Women Can Incur 'Catastrophic' Bills for Out-of-State Abortions, Study Finds
- First Cases of Sexually Transmitted Ringworm Reported in the U.S.
- FDA Approves Orlynvah (sulopenem etzadroxil and probenecid) for the Treatment of Uncomplicated Urinary Tract Infections
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions